Korean Drug Co Ltd
KOSDAQ:014570
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4 100
5 170
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| KR |
K
|
Korean Drug Co Ltd
KOSDAQ:014570
|
45B KRW |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| UK |
D
|
Dechra Pharmaceuticals PLC
F:1PK
|
5.1B EUR |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
529.7B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
275.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
210.3B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.9B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
269.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
Loading...
|
Market Distribution
| Min | -168 471.3% |
| 30th Percentile | -2.9% |
| Median | 1.9% |
| 70th Percentile | 5.8% |
| Max | 21 012.5% |
Other Profitability Ratios
Korean Drug Co Ltd
Glance View
KOREAN DRUG Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products. The company is headquartered in Icheon, Gyeonggi-Do and currently employs 256 full-time employees. The company went IPO on 2000-12-07. The Company’s products portfolio consists of over-the-counter (OTC) medicines, ethical (ETC) medicines and health food, including multi-symptom cold medicines, blood-forming nutrients, treatments for central nervous system, remedies for respiratory diseases, dermatological agents, vitamins, antifungal agents, antipyretics, analgesics, anti-inflammatory drugs, antibiotics, allergic treatments, calcium and vitamin D tablets and home pregnancy test kits, among others.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Korean Drug Co Ltd is 4.4%, which is above its 3-year median of 3.4%.
Over the last 3 years, Korean Drug Co Ltd’s Net Margin has decreased from 14.6% to 4.4%. During this period, it reached a low of -6.6% on Mar 31, 2024 and a high of 15.6% on Mar 31, 2023.